Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study

Journal of Clinical Oncology

Volumn 34, Issue 27, 2016, Pages 3293-3299

  Santoro, Armando ^a,b   Mazza, Rita ^a   Pulsoni, Alessandro ^c   Re, Alessandro ^d   Bonfichi, Maurizio ^e   Zilioli, Vittorio Ruggero ^f   Salvi, Flavia ^h   Merli, Francesco ⁱ   Anastasia, Antonella ^d   Luminari, Stefano ^j   Annechini, Giorgia ^c   Gotti, Manuel ^e   Peli, Annalisa ^d   Liberati, Anna Marina ^k   Di Renzo, Nicola ^l   Castagna, Luca ^a   Giordano, Laura ^a   Carlo Stella, Carmelo ^a,g  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SPEDALI CIVILI   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h C Arrigo Children's Hospital   (Italy)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k Santa Maria University Hospital   (Italy)

^l VITO FAZZI HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENDAMUSTINE; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOTEMUSTINE; GEMCITABINE; MELPHALAN; NAVELBINE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; DEOXYCYTIDINE; VINORELBINE TARTRATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CD34 SELECTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; STEM CELL MOBILIZATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; VERTIGO; WEIGHT CHANGE; ADOLESCENT; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE; YOUNG ADULT;

EID: 84989812251     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.4466     Document Type: Article

References (35)

1. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
2. Canellos GP, Rosenberg SA, Friedberg JW, et al: Treatment of Hodgkin lymphoma: A 50-year perspective. J Clin Oncol 32:163-168, 2014
3. Rancea M, von Tresckow B, Monsef I, et al: High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: A systematic review with meta-analysis. Crit Rev Oncol Hematol 92:1-10, 2014
4. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
5. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002
6. Castagna L, Carlo-Stella C, Mazza R, et al: Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Mediterr J Hematol Infect Dis 7:e2015015, 2015
7. Castagna L, Crocchiolo R, Giordano L, et al: High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant 50:499-504, 2015
8. Santoro A, Magagnoli M, Spina M, et al: Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92:35-41, 2007
9. Magagnoli M, Spina M, Balzarotti M, et al: IGEV regimen and a fixed dose of lenograstim: An effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant 40:1019-1025, 2007
10. van der Jagt R: Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: A review of pharmacokinetics and clinical trial outcomes. Expert Rev Hematol 6:525-537, 2013
11. Moskowitz AJ, Hamlin PA Jr, Perales MA, et al: Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31:456-460, 2013
12. Corazzelli G, Angrilli F, D'Arco A,et al: Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 160:207-215, 2013
13. Zinzani PL, Derenzini E, Pellegrini C, et al: Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Br J Haematol 163:681-683, 2013
14. Ghesquières H, Stamatoullas A, Casasnovas O, et al: Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: A retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma 54:2399-2404, 2013
15. Anastasia A, Carlo-Stella C, Corradini P, et al: Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: A retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 166:140-142, 2014
16. Josting A, Rudolph C, Mapara M, et al: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16:116-123, 2005
17. Erratum Josting A, Rudolph C, Mapara M, et al: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 19:1515, 2008
18. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
19. Moskowitz CH, Nimer SD, Zelenetz AD, et al: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 97:616-623, 2001
20. Josting A, Müller H, Borchmann P, et al: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 28:5074-5080, 2010
21. Kuruvilla J, Nagy T, Pintilie M, et al: Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106:353-360, 2006
22. Carbone A, Gloghini A, Castagna L, et al: Primary refractory and early-relapsed Hodgkin's lymphoma: Strategies for therapeutic targeting based on the tumour microenvironment. J Pathol 237:4-13, 2015
23. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012
24. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010
25. Gopal AK, Ramchandren R, O'Connor OA, et al: Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120:560-568, 2012
26. Carlo-Stella C, Ricci F, Dalto S, et al: Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four Italian centers. Oncologist 20:323-328, 2015
27. Zinzani PL, Viviani S, Anastasia A, et al: Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 98:1232-1236, 2013
28. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015
29. Hawkes EA, Grigg A, Chong G: Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 16:e234-e245, 2015
30. Armand P: Immune checkpoint blockade in hematologic malignancies. Blood 125:3393-3400, 2015
31. Moskowitz CH, Ribrag V, Michot J-M, et al: PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study (KEYNOTE-013). Blood 124, 2014 (abstr 290)
32. Armand P, Shipp MA, Ribrag V, et al: PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Safety, efficacy, and biomarker assessment. Blood 126, 2015 (abstr 584)
33. Garcia-Sanz R, Sureda A, Alonso-Alvarez S, et al: Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: Preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood 126, 2015 (abstr 582)
34. LaCasce AS, Bociek G, Sawas A, et al: Brentuximab vedotin plus bendamustine: A highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood 126, 2015 (abstr 3982)
35. Sawas A, Connors JM, Kuruvilla JG, et al: The combination of brentuximab vedotin (Bv) and bendamustine (B) demonstrates marked activity in heavily treated patients with relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL): Results of an international multi center phase I/II experience. Blood 126, 2015 (abstr 586)